Diagnostic Criteria and Treatment Options for Major Depressive Disorder

Diagnostic Criteria for MDD

The American Psychiatric Association defines MDD as depressed mood or loss of pleasure/interest along with other symptoms that last for at least 2 weeks and affect normal functioning 1
Diagnosis requires at least 5 symptoms during a 2-week period, including depressed mood, anhedonia, insomnia or hypersomnia, psychomotor agitation or retardation, and fatigue or loss of energy 1
The Mini International Neuropsychiatric Interview or Structured Clinical Interview can be used for diagnosis based on DSM-5 criteria 2

Assessment Tools

The Patient Health Questionnaire-9 (PHQ-9) and Hamilton Depression Rating Scale (HAM-D) are used to assess depression severity and monitor treatment response 1
The Montgomery-Åsberg Depression Rating Scale (MADRS) and Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) are recommended for assessing depression severity 3
Response to treatment is typically defined as ≥50% reduction in measured severity using validated tools 1

First-Line Treatment Options

The American College of Physicians strongly recommends either cognitive behavioral therapy (CBT) or second-generation antidepressants (SGAs) as first-line treatment for MDD 4, 5, 6
CBT and SGAs have similar effectiveness as first-line treatments, based on moderate-quality evidence 6

Pharmacotherapy Options

Second-generation antidepressants, particularly SSRIs or SNRIs, are recommended first-line pharmacological treatments 7
Treatment should be continued for at least 4-9 months after satisfactory response for first episodes, with longer duration beneficial for recurrent episodes 7

Psychotherapy Options

Cognitive Behavioral Therapy (CBT) has moderate-quality evidence supporting its effectiveness as equivalent to SGAs 4, 7

Treatment Phases

Depression treatment follows three distinct phases: acute phase (6-12 weeks), continuation phase (4-9 months), and maintenance phase (≥1 year) 1, 7

Treatment-Resistant Depression

Treatment-resistant depression (TRD) is defined as failure to respond to two or more adequate antidepressant trials 2
An adequate trial requires sufficient dose and duration (typically minimum 4 weeks) 2

Common Pitfalls to Avoid

Inadequate dosing or premature discontinuation before therapeutic effects are achieved (typically 4-6 weeks) 7
Failure to monitor for suicidality, especially during initial treatment period 7
Not continuing treatment long enough to prevent relapse (minimum 4-9 months after response) 7

Diagnostic and Treatment Considerations for Major Depressive Disorder

Severity Classification and Treatment Approach

The severity classification of Major Depressive Disorder (MDD) is based on symptom count, intensity, and functional impairment, with the American Academy of Pediatrics recommending consideration of these factors in treatment planning 8
For patients with mild depression, the American College of Physicians suggests starting with cognitive behavioral therapy (CBT) alone, as it has equivalent effectiveness to antidepressants, with moderate-quality evidence 9
The American College of Physicians also recommends initiating second-generation antidepressants for moderate to severe depression, selected based on adverse effect profiles, cost, and patient preferences 9
In cases of severe depression with high-risk features, the American Academy of Pediatrics advises classifying as severe regardless of symptom count and initiating antidepressants immediately with close monitoring 8

Treatment Monitoring and Adjustment

The Annals of Internal Medicine recommends assessing response to treatment within 1-2 weeks of initiation, monitoring for therapeutic effects, adverse effects, and suicidality 9
If there is an inadequate response to treatment by 6-8 weeks, the Annals of Internal Medicine suggests modifying treatment, including dose adjustment, switching agents, or adding augmentation strategies 9
The Annals of Internal Medicine also recommends continuing treatment for 4-9 months after satisfactory response for first episodes, and longer duration (≥1 year) for recurrent episodes 9

Assessment and Treatment of Major Depressive Disorder

Diagnostic Criteria and Assessment

The American Psychiatric Association recommends assessing for accompanying symptoms including insomnia, low energy, and somatization in patients with major depressive disorder 10

Comorbidity Assessment

The National Institute of Mental Health suggests evaluating for substance use disorders, which are common in untreated depression, and screening for comorbid anxiety disorders, as patients with both conditions experience more chronic illness course, increased suicidal thoughts, and greater functional impairment 10

Treatment Options

The American Medical Association recommends initiating second-generation antidepressants (SSRIs or SNRIs) selected based on adverse effect profiles, cost, and patient preferences, with similar effectiveness to cognitive behavioral therapy (CBT) 11

Optimal Treatment for Severe Major Depressive Disorder with Anhedonia

Rationale for Combination Therapy

The American College of Physicians recommends combination therapy (psychotherapy + antidepressant) for severe major depressive disorder, as it produces statistically superior outcomes compared to antidepressant monotherapy, with remission rates nearly doubling (57.5% vs 31.0%, P < 0.001) and response rates increasing substantially (78.7% vs 45.2%, P < 0.001), in patients with severe depression, including those with anhedonia and prior partial response to SSRIs 12, 13
Combination therapy, including dynamic interpersonal therapy and general supportive therapy combined with SSRIs or SNRIs, has been shown to be effective in achieving higher remission and response rates in patients with severe major depressive disorder 13
The benefit of combination therapy is consistent across multiple studies and represents the highest quality recent evidence for severe major depressive disorder, with a strength of evidence considered high 12

Pharmacotherapy Selection

The American Academy of Family Physicians suggests that SNRIs (such as venlafaxine) are slightly more effective than SSRIs for improving depression symptoms, though they carry higher rates of nausea and vomiting, and may be a preferred option for patients with severe major depressive disorder and anhedonia 14
Alternative SSRIs (such as escitalopram or citalopram) may be considered if SNRI side effects are concerning, due to their favorable tolerability profiles and lack of sedating properties 14

Psychotherapy Component

The American College of Physicians strongly recommends initiating cognitive behavioral therapy (CBT) concurrently with pharmacotherapy, not sequentially, for patients with severe major depressive disorder, including those with anhedonia and prior partial response to SSRIs, as CBT has moderate-quality evidence supporting effectiveness equivalent to SGAs when used alone, and superior outcomes when combined with medication 12, 15
CBT has been shown to be effective in reducing symptoms of depression and improving quality of life in patients with severe major depressive disorder, with a strength of evidence considered moderate 15

Treatment Duration and Monitoring

The American College of Physicians recommends continuing treatment for at least 4-9 months after satisfactory response for patients with severe major depressive disorder, including those with anhedonia and prior partial response to SSRIs, to prevent relapse 15
Patients with recurrent depression may benefit from prolonged treatment (≥1 year or longer), as suggested by the American Academy of Family Physicians 14, 16

Treatment Approach for Continued Depression

Defining Treatment Resistance

The patient meets criteria for treatment-resistant depression (TRD), defined as failure to respond to two or more adequate antidepressant trials, with both treatment failures within the current episode and proper documentation of adherence 17, 18
Before proceeding further, it is essential to confirm that the vilazodone trial has been adequate, with a minimum of 4 weeks at 40mg (the maximum FDA-approved dose) and documented adherence 17, 18
The 2022 Molecular Psychiatry consensus guidelines emphasize the importance of proper documentation of adherence, considering checking plasma levels if adherence is uncertain 17, 19

Critical Monitoring Parameters

Adherence issues should not be overlooked, as up to 50% of patients with MDD demonstrate non-adherence, which can masquerade as treatment resistance 17, 18

Alternative Strategies

The American College of Physicians strongly recommends adding Cognitive Behavioral Therapy (CBT) to pharmacotherapy for treatment-resistant depression, producing statistically superior outcomes compared to antidepressant monotherapy 20, 21

Psychobiotics in the Treatment of Major Depressive Disorder – Guideline Summary

Guideline Position on Psychobiotics

Established First‑Line Treatments

Evidence‑Based Complementary and Alternative Medicine (CAM)

Adjunctive Strategies for Inadequate Response to First‑Line Therapy

Evidence Gaps and Quality Considerations

Evidence‑Based Management of Major Depressive Disorder

Initial Assessment and Diagnosis

Confirm the diagnosis of major depressive disorder using DSM‑5 criteria (≥5 symptoms for ≥2 weeks, including depressed mood or anhedonia) before initiating treatment. 27
Conduct structured interviews with the individual and their family or caregivers to evaluate functional impairment in work/school, home, and social domains. 28
Screen routinely for comorbid anxiety disorders, substance‑use disorders, and bipolar spectrum conditions, as these comorbidities markedly influence prognosis and therapeutic choices. 28
Perform an immediate suicide‑risk assessment at every encounter, documenting any specific plan, intent, recent attempts, psychotic features, and relevant family history. 28

Severity‑Based Treatment Algorithm

Mild Depression (5–6 symptoms, minimal functional impact)

Offer cognitive‑behavioral therapy (CBT) as the sole first‑line intervention; moderate‑quality evidence shows CBT is as effective as antidepressants while avoiding medication side‑effects. 27

Moderate Depression (7–8 symptoms, moderate functional impact)

Initiate either CBT or a second‑generation antidepressant (selective serotonin‑reuptake inhibitor [SSRI] or serotonin‑norepinephrine reuptake inhibitor [SNRI]) as monotherapy; moderate‑quality evidence indicates comparable remission rates between these modalities. 27
Choose the specific antidepressant based primarily on side‑effect profile, cost, and patient preference rather than on efficacy differences. 27

Severe Depression (≥9 symptoms, severe functional impact, or high‑risk features)

Begin combination therapy with both an antidepressant (SSRI or SNRI) and CBT concurrently; this strategy nearly doubles remission rates (≈57 % vs 31 %) compared with antidepressant monotherapy. 27
Hospitalize when acute safety concerns (e.g., imminent suicide risk or psychosis) are present. 28

High‑Risk Features Defining Severe Depression

Presence of a specific suicide plan, intent, recent attempt, active psychotic symptoms, or a first‑degree relative with bipolar disorder warrants classification as severe depression regardless of symptom count. [28][29]

Safety Planning (Required for All Patients)

Develop a written safety plan at the initial visit that (1) limits access to lethal means, (2) identifies a responsible third party for monitoring, and (3) establishes an emergency communication protocol. 28
Explicitly discuss limits of confidentiality with the individual and their support network. 28
Recognize that safety concerns peak during the early treatment phase and therefore require the most intensive monitoring. 28

Treatment Monitoring

Re‑assess therapeutic response, adverse effects, and emergence of suicidality within 1–2 weeks of treatment initiation. 28

All bullet points are derived from peer‑reviewed evidence (Annals of Internal Medicine 2023; Pediatrics 2018) and reflect the strength of evidence where reported (moderate‑quality where noted).